Intellia Therapeutics Inc (NTLA) Stock Price Down 3.5%
Intellia Therapeutics Inc (NASDAQ:NTLA) shares were down 3.5% during mid-day trading on Wednesday . The company traded as low as $19.21 and last traded at $19.39, with a volume of 100,419 shares trading hands. The stock had previously closed at $20.10.
A number of research analysts have issued reports on NTLA shares. Jefferies Group upgraded Intellia Therapeutics from a “hold” rating to a “buy” rating and set a $33.00 price objective for the company in a research note on Friday, August 5th. Zacks Investment Research upgraded Intellia Therapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday. Leerink Swann started coverage on Intellia Therapeutics in a research note on Tuesday, May 31st. They issued a “market perform” rating and a $32.00 price objective for the company. Wedbush restated an “outperform” rating and issued a $38.00 price objective on shares of Intellia Therapeutics in a research note on Tuesday, August 23rd. Finally, Credit Suisse Group AG started coverage on Intellia Therapeutics in a research note on Tuesday, May 31st. They issued an “outperform” rating and a $39.00 price objective for the company. One equities research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. The stock currently has an average rating of “Buy” and a consensus price target of $35.50.
The stock’s market capitalization is $708.74 million. The firm has a 50-day moving average of $19.50 and a 200-day moving average of $22.85.
Intellia Therapeutics, Inc is a United States-based genome editing company focused on the development of curative therapeutics using a biological tool, CRISPR/Cas9 system. The Company’s CRISPR/Cas9 technology edits diseased genes in the human body through a single treatment course. It focuses on the therapeutic applications of CRISPR/Cas9 genome editing.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.